Search results
Swirling Global Uncertainties Make It a Great Time to Be a Greek Shipowner
Bloomberg via Yahoo Finance· 18 hours ago(Bloomberg) -- Sandwiched between the world’s great global powers in a time of deepening global...
Aptevo Participating in the BIO International Convention
Morningstar· 15 hours ago(Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, < ...
EMEA Morning Briefing: Shares Set to Gain Amid Rate-Cut Hopes
Morningstar· 23 hours agoMARKET WRAPS Watch For: Manufacturing PMI for EU, Germany, France, Italy, UK; no major corporate updates expected Opening Call: Shares are poised to start higher in Europe ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 7 days agoWYNDHAM HOTELS & RESORTS COMPLETES SUCCESSFUL DEBT REPRICING AND UPSIZING PR Newswire PARSIPPANY, N.J., May 28, 2024 PARSIPPANY, N.J., May 28, 2024 /PRNewswire/ -- Wyndham Hotels & Resorts, ...
On-the-Record Press Gaggle by White House National Security Communications Advisor John Kirby | The...
The White House· 5 days agoToday, the Secretary of the Army is in Mesquite, Texas, for the opening of a new factory that will...
The Motley Fool: Try on Nike stock for size
Dallas Morning News· 2 days agoNike stock slumped after its third-quarter earnings report, which featured weak revenue growth and disappointing projections. The stock’s value has...
OTR: Mass. congressman says Trump's conviction raises stakes of 2024 election
WCVB Boston· 1 day agoCONGRESSMAN SETH MOULTON IS OUR GUEST THIS MORNING. THE CONGRESSMAN IS IN THE CHAIR. AS YOU CAN SEE...
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR...
Morningstar· 6 days agoEfficacy and safety of AFM24 in combination with atezolizumab, a checkpoint inhibitor, is being evaluated in non-small cell lung cancer patients with EGFR wild-type and EGFR mutant advanced/ ...
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily...
Morningstar· 2 days agoIn 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved 4 objective responses; 3 of 4 responses were ...
Veeva Announces Fiscal 2025 First Quarter Results
Yucaipa News Mirror· 4 days agoVeeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its first quarter ended ...